产品
编 号：F715264
分子式：C25H27Cl3FN7
分子量：550.89
分子式：C25H27Cl3FN7
分子量：550.89
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2247953-39-3
产品详情
生物活性：
AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 μΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1.
体内研究：
Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone.Animal Model:Balb/c Mice (Mouse Colorectal Cancer Model CT26)
Dosage:10 mg/kg (combination with anti-PD-1)
Administration:P.o.; every day for 3 weeks
Result:Significantly inhibited tumor growth inhibition.
AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 μΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1.
体内研究：
Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone.Animal Model:Balb/c Mice (Mouse Colorectal Cancer Model CT26)
Dosage:10 mg/kg (combination with anti-PD-1)
Administration:P.o.; every day for 3 weeks
Result:Significantly inhibited tumor growth inhibition.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备